VOR - Indikator likuiditas cepet vorbio.com

Simbol resmi perusahaan Vor Bio (VOR)

The price chart for Vor Biopharma Inc. (VOR) reflects the impact of positive data from initial bone marrow protection system tests, with the current indicator standing at 19.76. The business relies on partnerships with transplant centers to create synergy in cell editing. Complex biosyntheses and patent protection ensure a high barrier to entry, effectively excluding new players.

Vor Bio (VOR) - Likuiditas cepet saka 04.07.2022 nganti 29.10.2026

Rincian analitis perusahaan Vor Biopharma Inc.

- nilai pasar lan prakiraan target analis:
Bagan rega Vor Bio|VOR - Konsensus nilai wajar
- statistik kapitalisasi pasar:
Biji pasar Vor Bio|VOR - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Vor Biopharma|VOR - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku vorbio.com|VOR - Aset Agregat Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Vor Biopharma Inc.|VOR - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Vor Biopharma|VOR - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Vor Bio|VOR - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Vor Biopharma|Likuiditas cepet vorbio.com
- indikator bathi lan kelipatan valuasi:
VOR - Penghasilan resik perusahaan
Analisis komprehensif perusahaan:Vor Bio - VOR
Produk asil prodhuksi Vor Biopharma

The quick ratio is calculated as the ratio of cash and accounts receivable to current liabilities, completely excluding illiquid inventories. This coefficient serves as a stringent indicator of financial stability and the company's ability to promptly settle its debts. For Vor Biopharma Inc. (VOR), this margin of safety is critical until the commercialization of its unique cell therapy. The trend in the average quick ratio allows for an assessment of the capital burn rate for research and development.

Pesaing wigati

TG Therapeutics Corp (TGTX) - Likuiditas cepet|Arcellx Therapeutics - Rasio jangkoan perantara|Indikator likuiditas cepet IRON|SNDX: Rasio jangkoan perantara|Rasio cepet KURA|Likuiditas cepet ADCT (ADC Therapeutics S.A.)|Likuiditas cepet Foghorn Therapeutics Inc. FHTX|Nkarta Inc. - Likuiditas cepet|COEP - Likuiditas cepet|Likuiditas darurat actiniumpharma.com|Estrella Immunopharma, Inc. (ESLA) - Likuiditas cepet|Likuiditas darurat CASI Pharmaceuticals, Inc. (CASI)|MRKR (Marker Therapeutics Inc) - Rasio cepet|Rasio likuiditas darurat INAB (IN8bio Inc)|Indikator likuiditas cepet ERNA (Eterna Therapeutics)|Likuiditas cepet GTBP (gtbiopharma.com)|Likuiditas cepet Aptose Biosciences APTO|Bio-Path Holdings Inc. (BPTH) - Likuiditas darurat|MEIP - Likuiditas cepet|Rasio jangkoan perantara VINC (Vincerx Pharma, Inc.)